Frequently, PSA screening for prostate cancer has limited sensitivity and specificity, which can lead to overdiagnosis and overtreatment of indolent disease, resulting in unnecessary, invasive biopsy and treatments for non-aggressive cancers [5,6]. This evidence concerns the gene KLK3 and Familial prostate cancer.